Morgan Stanley says there are still plenty of quality buying opportunities left ahead of earnings.
Related Posts
Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis products.
Hamas hands over three Israeli hostages to Red Cross in central Gaza
Hamas handed over on Saturday three Israeli hostages to the Red Cross in central Gaza’s Deir Al-Balah, live television showed.
David Einhorn is building new position in CNH Industrial, says agricultural play is ‘cheap’
The hedge fund investor said the agricultural machinery company is an under-the-radar value play as the industry nears the end of a bearish cycle.